Skip to content
OpenCapital
Get started

Zimmer Biomet Holdings ZBH US — PP&E (Net)

Similar metrics at other companies

Alphatec Holdings logo
ATECUS — PP&E (Net)
$136.84M-5.7%
Anika Therapeutics logo
ANIKUS — PP&E (Net)
$39.47M+4.0%
Merit Medical Systems logo
MMSIUS — PP&E (Net)
$300.59M+10.6%
Herbalife logo
HLFUS — PP&E (Net)
$399.7M-2.5%
Impinj, Inc. logo
PIUS — PP&E (Net)
$13.39M+1.0%
ADTRAN Holdings, Inc. logo
ADTNUS — PP&E (Net)
$49.3M+6.5%

Other financials

Income statement

See full
Revenue$2.1B+9.3%
Gross profit$1.5B+11.1%
Operating income$373.2M+27.7%
Net income$238.1M+30.8%
EPS (diluted)$1.22+34.1%

Balance sheet

See full
Cash & equivalents$424.2M-69.4%
Total debt$7.5B+4.1%
Total equity$12.7B+2.2%
Total assets$22.7B+2.4%

Cash flow

See full
Operating cash flow$359.4M-6.1%
CapEx$36.3M-18.6%
Free cash flow$323.1M-4.5%

Valuation

See full
Market cap$17.44B-7.4%
Enterprise value$24.49B-5.2%
P/E22.9×0.0×
P/S2.1×-0.3×

Profitability

See full
Gross margin70%-1.0pp
Operating margin14%-3.0pp
Net margin9.1%-2.8pp
FCF margin17.3%-1.6pp

Returns & leverage

See full
Return on equity6.1%-1.2pp
Debt / equity0.6×0.0×
Current ratio1.7×-0.7×

Where this comes from

Reported directly by Zimmer Biomet Holdings in its filing.

Tagged under the XBRL concept us-gaap:PropertyPlantAndEquipmentNet.

The official record: Zimmer Biomet Holdings’s 10-K, filed February 20, 2026, on SEC EDGAR. View the filing →

Ask your AI about Zimmer Biomet Holdings's us — pp&e (net).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Zimmer Biomet Holdings's US — PP&E (net)?
Zimmer Biomet Holdings (ZBH) reported US — PP&E (net) of $1.33B in Q4 2025.
How has Zimmer Biomet Holdings's US — PP&E (net) changed year-over-year?
Zimmer Biomet Holdings's US — PP&E (net) increased by 5.8% year-over-year, from $1.26B to $1.33B.
What does US — PP&E (net) mean?
This metric represents the net book value of tangible assets located within the United States, including manufacturing facilities, research laboratories, and specialized surgical equipment production sites. It is calculated as the historical cost of these assets minus accumulated depreciation and impairment charges. This figure reflects the company's investment in domestic infrastructure required to support its orthopedic manufacturing and distribution operations.